Clinical Significance of Anti-GM3 Antibodies in Recurrent Pregnancy Loss With Elevated Level of Antiphospholipid Antibodies
Article first published online: 9 MAY 2013
American Journal of Reproductive Immunology
Volume 33, Issue 3, pages 234–242, March 1995
How to Cite
OZAKI, Y., AOKI, K., AOYAMA, T. and KUNIMATSU, M. (1995), Clinical Significance of Anti-GM3 Antibodies in Recurrent Pregnancy Loss With Elevated Level of Antiphospholipid Antibodies. American Journal of Reproductive Immunology, 33: 234–242. doi: 10.1111/j.1600-0897.1995.tb00890.x
- Issue published online: 9 MAY 2013
- Article first published online: 9 MAY 2013
- Accepted August 22, 1994
- Anti-GM3 antibody;
- recurrent pregnancy loss;
- antiphospholipid antibodies
PROBLEM: The ganglioside-GM3 neutralizes the reactivity of antiphospholipid antibodies (APLs) to phospholipids in vitro. The question of whether anti-GM3 antibodies might exert influence in APLs-positive recurrent pregnancy loss patients who are undergoing prednisolone and aspirin (PSL/ASA) treatment was investigated.
METHOD: The anti-GM3 antibody assay of sera was accomplished by ELISA. Sera of 56 patients with recurrent pregnancy loss, including 30 APLs-positive cases given PSL/ASA treatment, were examined.
RESULTS: Patients positive for IgG or IgM type anti-GM3 antibodies constituted 13/30 (43%) of the APLs-positive group as compared with only 2/26 (8%) of those who were negative (P<0.01). In pregnant women with APLs-positive treated with PSL/ASA, live births occurred in only 6/13 (46%) patients with detectable anti-GM3 antibodies, while in 16/17 (94%) who tested negative for anti-GM3 antibodies (P<0.01).
CONCLUSIONS: This observation suggests the possibility that presence of anti-GM3 antibodies may be an indicator for determining the prognosis in recurrent pregnancy loss with elevated level of APLs.